key: cord-0956409-3uh9mwnb
authors: Jiang, Fei; Xu, Nana; Zhou, Yanxi; Song, Jinxing; Liu, Jinjuan; Zhu, Hong; Jiang, Jihong; Xu, Yonghong; Li, Rongpeng
title: Contribution of traditional Chinese medicine combined with conventional western medicine treatment for the novel coronavirus disease (COVID‐19), current evidence with systematic review and meta‐analysis
date: 2021-07-13
journal: Phytother Res
DOI: 10.1002/ptr.7209
sha: 7ff7f91328f4128da71ddb9ed0a90c8e121be38e
doc_id: 956409
cord_uid: 3uh9mwnb

This study provides current evidence for efficacy and safety of treating COVID‐19 with combined traditional Chinese medicine (TCM) and conventional western medicine (CWM). Six databases were searched from January 1 to December 31, 2020. Randomized controlled trials (RCTs), case–control studies (CCTs), and cohort studies on TCM or TCM combined with CWM treatment for COVID‐19 were included. The quality of included RCTs was assessed by Cochrane risk of bias tool, and the Newcastle‐Ottawa Scale (NOS) was used to assess the quality of cohort studies and CCTs. Review Manager 5.4 software was used to perform meta‐analysis. The quality of evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. A total of 35 studies (3,808 patients) composing 19 RCTs and 16 observational studies were included. The results of meta‐analysis revealed that comparing with CWM alone, integrated TCM and CWM had significant improvement in total effective rate, improvement rate of chest CT, the rate of disease progression, as well as improvement of fever, fatigue and cough. The overall quality of evidence was very low to moderate. In conclusion, TCM combined with CWM was a potential treatment option for increasing clinical effective rate, improving the clinical symptoms, and preventing disease progression in COVID‐19 patients. High‐quality clinical trials are required in the further.

Since December 2019, a novel positive strand RNA coronavirus named SARS-COV-2 was confirmed to be the pathogen causing an outbreak of unexplainable pneumonia . The rapid human-to-human transmission and the lack of specific antiviral drugs and vaccines have resulted in an outbreak of coronavirus disease 2019 in 212 countries and regions around the world. By the end of 2020, so far, the cumulative number of confirmed cases has reached more than 70 billion, and the cumulative number of deaths has reached more than 1.6 million. Although the epidemic has subsided in China, the number of new confirmed cases overseas is on the rise. The COVID-19 remains a major threat to global public health.

In China, traditional Chinese medicine (TCM) combined with conventional western medicine (CWM) has been a great success in the treatment of COVID-19. During this COVID-19 outbreak, over 90% of total confirmed COVID-19 patients in China had been treated with TCM or TCM combined with CWM (News Conference of the State Council Information Office, 2020). Related reports including case reports, observational studies and randomized clinical trials had confirmed that integrated TCM and CWM could increase clinical effective rate, improve the clinical symptoms, shorten length of hospital stay, and reduce patient number of transferred to severe or critically ill cases Tian et al., 2020; Xiao, Tian et al., 2020; Zhang, Tian et al., 2020) . Moreover, a number of systematic reviews have assessed the efficacy and safety of TCM for treating COVID-19 (M. Liu et al., 2020; Luo et al., 2020; Pang et al., 2020; . But the previous systematic reviews included a maximum of 11 RCTs (Pang et al., 2020) . The limited number of literature included in these reviews provided limited TCM treatment schemes because TCM emphasizes perspective of harmonization between environment and human body, different provinces released different treatment guidance according to the disease, local climate characteristics, and different physical conditions. A summary at a time when the epidemic in China is leveling off was performed to provide complete guidance for clinical practice.

This review protocol has been registered in the International Prospective Register of Systematic Reviews (PROSPERO registration number: CRD42020201639). This study was based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) (Moher, Liberati, Tetzlaff, Altman, & PRISMA Group, 2009 ).

Randomized controlled trials (RCTs), cohort studies and casecontrolled studies (CCTs) were included in this systematic review.

Publications in English and Chinese were included.

Participants confirmed with COVID-19 were included regardless of their age, sex, race, and nationality. Diagnostic criteria consisted of the following: (a) historical epidemiology; (b) being symptomatic (either having fever, coughing, or fatigue) plus radiologic abnormalities consistent with pneumonia; (c) positive for SARS-CoV-2 nucleic acid tests; (d) the gene sequence of the virus was highly homologous to the known novel coronavirus. Patients who simultaneously met the (a) and (b), any one of (c), and (d) following criteria were included. 

The primary outcome was rate of disease progression (proportion of patients who have progressed from mild or ordinary types to severe or critical types after treatment), negative conversion rate of nucleic acid (proportion of patients whose nucleic acid test become negative after treatment), and improvement rate of chest CT (number of patients whose CT lesions disappeared or decreased after treatment as a percentage of all patients treated). The secondary outcomes were total effective rate (number of patients cured plus the number in remission per group divided by the total number of patients in each group), incidence of adverse events (number of patients with side effects after treatment as a percentage of all patients treated), disappearance rate of main symptoms (number of patients whose symptoms [fever, cough, and fatigue] disappeared after treatment as a percentage of all patients treated), lymphocyte count, and length of hospital stay.

The exclusion criteria were as follows: self-control or lack of control, case report and case series, cross-sectional study, experience summary, animal experiment research, systematic review and meta-analysis, and full texts were not available. 

The RoB2 assessment form (revised tool for risk of bias in randomized trials) was used for assessing RCTs in following five fields: randomisation process, deviation from intended interventions, missing outcome data，measurement of the outcome, and selection of the reported result (Sterne et al., 2019) . Each field was assessed to be "low risk", "high risk", or "some concerns". The Newcastle-Ottawa Scale (NOS) assesses the quality of cohort studies and CCTs with the following three broad categories: selection, comparability and exposure, or outcome (Wells et al., 2003) . The total score is 9, the higher the score, the better the quality of the study. Two reviewers (F. Jiang and N.N. Xu) independently completed the data extraction and quality assessment. Any disagreement was resolved by discussion or consultation with a third reviewer (Y.X. Zhou).

Review Manager (version 5.4) was used to perform the statistical analysis. The effect measure of binary variable would be expressed as risk ratio (RR) or odds ratio (OR) and 95% confidence interval (CI). For continuous variables, 95% CI and mean difference (MD) or standardized mean difference (SMD) would be used. We assessed statistical heterogeneity in each pairwise comparison with I 2 test. If I 2 ≤ 50% and p > .05, the heterogeneity among included studies was considered low. If I2 > 50% or p ≤ .05, the heterogeneity among included studies was considered high. Considering the heterogeneity of TCM interventions, the random effects models would be used to calculate the effect size. If there was a significant level of heterogeneity and available data were enough, sensitivity analysis or subgroup analysis would be conducted. The publication bias was evaluated by funnel plot, and it is determined by observing whether the left and right were symmetrical. If the left and right were not symmetrical, there is a bias.

Considering that observational studies are of low-quality evidence and that there are factors that reduce the quality of evidence, leading to a very low quality of evidence, we only evaluated the quality of evidence for RCTs. According to the GRADE approach, the quality of RCTs can be downgraded for five reasons (risk of bias, imprecision, inconsistency, indirectness, and publication bias). Summary of Findings table was created by GRADE online (https:// gradepro.org/).

A total of 5,697 articles were retrieved, including 3,685 duplicates.

According to the inclusion and exclusion criteria, 1967 articles were removed based on their titles and abstracts. Forty-five full-text articles were assessed for eligibility, and 10 articles were excluded due to following reasons: ① Duplicates (n = 5); ② Observation group did not meet the inclusion criteria (n = 2); ③ Including suspected case (n = 1); ④ Article retracted (n = 1); ⑤ Cross-sectional study (n = 1).

Thirty-five clinical studies were included in this systematic review.

The process of study screening is shown in Figure 1 .

Basic characteristic of enrolled studies are summarized in Table 1 .

Five articles were published in English, and 30 studies were published in Chinese. Among the 35 clinical trials, 19 were RCTs Duan et al., 2020; Fu, Lin, & Tan, 2020a , 2020b Liao, 2020; Pan et al., 2020; Qiu et al., 2020; Sun et al., 2020; Wang, Wang, et al., 2020; Wang, Yang, et al., 2020; Wen, Zhou, Jiang, & Huang, 2020; Xiao, Tian et al., 2020; Yu, Li, Wan, & Wang, 2020; Zhang, Lei, Xu, Wei, & Hu, 2020; Zheng et al., 2020; Zhou, Zhao, Li, & Tian, 2020) , 14 were CCTs Cheng et al., 2020; Ji, Feng, & Fei, 2020; Lian et al., 2020; F. Liu, 2020; Qu et al., 2020; Shi et al., 2020; Xiao, Jiang, et al., 2020; Yang, Dang, Huang, Li, & Guo, 2020; Yang, Sun, et al., 2020; Yao, Liu, Li, Huang, & Cai, 2020; Zhang, Huang et al., 2020) and 2 were retrospective cohort study Xia et al., 2020) . Totally, 3,808 patients including 2077 patients in the intervention group and 1731 patients in the control group were enrolled, with the sample size ranged from 12 to 721. In the intervention group, COVID-19 patients were all treated by integrated TCM and CWM, while patients were treated by CWM alone in the control group. TCM used in these studies including Chinese patent medicine (n = 14) and Chinese herbal decoction (n = 20) and injection (n = 1).

The compositions of TCM were summarized in Table S3 . Treatment duration varied from 5 to 15 days. The outcome measure of concern is total effective rate, improvement of chest CT, adverse events, negative conversion of nucleic acid, relief rate and relief time of main clinical symptom, rate of disease progression and length of stay.

The risk of bias of the included RCTs was shown in Figure 2 . Among the included 19 studies, nine studies had low risk of bias, eight studies had some concerns and two studies had high risk of bias.

Sixteen observational studies including 14 CCTs and 2 retrospective cohort studies (RCSs) were assessed for quality by the NOS. The range of scores was 6 to 8. These studies showed a moderate quality sufficient to conduct a meta-analysis (Table 2 ).

Rate of disease progression was reported in 21 studies Cheng et al., 2020; Duan et al., 2020; Fu et al., 2020b; Huang, Wang, et al., 2020; Huang, Tan, et al., 2020; Ji et al., 2020; Lian et al., 2020; F. Liu, 2020; Qiu et al., 2020; Shi et al., 2020; Sun et al., 2020; Tian et al., 2020; Wang, Wang, et al., 2020; Xia et al., 2020; Xiao, Tian, et al., 2020; Yang, Dang, et al., 2020; Yu et al., 2020; Zhang, Lei, et al., 2020) . Compared with the CWM group, the TCM + CWM group significantly reduced the rate of conversion to severe cases, the difference was 

3.3.2 | Negative conversion rate of nucleic acid

The negative conversion rate of nucleic acid after treatment was analyzed in 6 studies Pan et al., 2020; Qu et al., 2020; Wen et al., 2020; Yang, Dang, et al., 2020; Zhang, Lei, et al., 2020) . 

The main clinical symptoms are summarized in 

(1)(2)(3)(4)(5)(6) (7) (8)(9)(10)

Abbreviations: CCT, case-control study; RCS, retrospective cohort study; RCT, randomized controlled trial;

À, lack of data. a (1) Total effective rate; (2) Fever improvement; (3) Fatigue improvement; (4) Cough improvement; (5) negative conversion rate of nucleic acid; (6) chest CT improvement; (7) rate of conversion to severe cases; (8) Adverse events; (9) Peripheral blood index; (10) length of stay. et al., 2020; Ding et al., 2020; Duan et al., 2020; Ji et al., 2020; Liao, 2020; Sun et al., 2020; Wang, Yang, et al., 2020; Xiao, Tian, et al., 2020; Xiong, Wang, Du, & Ai, 2020; Yao et al., 2020; Zhang, Lei, et al., 2020) reported relief rate of fever symptom, and eleven studies Cheng et al., 2020; Huang, Tan, et al., 2020; Huang, Wang, et al., 2020; F. Liu, 2020; Qiu et al., 2020; Qu et al., 2020; Xia et al., 2020; Xiao, Jiang, et al., 2020; Zhang, Huang, Tan et al., 2020) reported fever relief time. Metaanalysis revealed statistically significant between the TCM + CWM group and the CWM group in fever relief rate (RR = 1.20, 95% CI = [1.05, 1.37], I 2 = 86%, p = .008) and fever reduction time (MD = -1.54, 95%CI = [À1.91, À1.17], I 2 = 54%, p < .00001). A significant heterogeneity was identified in fever relief rate. We conducted a sensitivity analysis by removing studies and recalculated the combined estimate on remaining studies. The I 2 become 13% after removing "Zhang YL 2020" and "Xiao MZ 2020" at the same time,

indicating that these two studies were the main sources of heterogeneity. For fever reduction time, the value of I 2 was 14% after removing "Xiao Q 2020", varying that this study was the source of heterogeneity.

Fatigue relief rate was reported in 11 studies Cheng et al., 2020; Duan et al., 2020; Ji et al., 2020; Liao, 2020; Sun et al., 2020; Xiao, Tian, et al., 2020; Yao et al., 2020; Zhang, Lei, et al., 2020) , and fatigue relief time was reported in 7 studies Cheng et al., 2020; Huang, Tan, et al., 2020; Huang, Wang, et al., 2020; Qu et al., 2020; Xiao, Jiang, et al., 2020) . "Zhang YL 2020" and "Xiao Q 2020" were the source of heterogeneity. I 2 become 21 and 0%, respectively, after removing these two studies.

The effect of TCM on cough relief rate and cough relief time was evaluated in 11 studies Cheng et al., 2020; Ding et al., 2020; Duan et al., 2020; Ji et al., 2020; Liao, 2020; Xiao, Tian, et al., 2020; Yao et al., 2020; Zhang, Lei, et al., 2020) and 8 studies Cheng et al., 2020; Huang, Tan, et al., 2020; Huang, Wang, et al., 2020; Qiu et al., 2020; Qu et al., 2020; Xiao, Jiang, et al., 2020) respectively. A significant improvement on cough relief rate (RR = 1.35, [1.14, 1.59], I 2 = 59%, p = .0003) and cough relief time (MD = À1.96, [À2.88, À1.04], I 2 = 84%, p < .0001) was observed by the TCM + CWM group. Removing "Xiao MZ 2020" and "Xiao Q 2020" separately in two outcome measures above, values of I 2 were all reduced to less than 50%.

For these studies considered to be the source of heterogeneity, we found that there was not statistically significant (p < .05) in relevant outcome measurements between the TCM + CWM group and the CWM group. 

The main peripheral blood indexes are summarized in Table 3 . The effect of TCM on white blood cell count and lymphocyte count was evaluated in 10 Fu et al., 2020a Fu et al., , 2020b Huang, Tan, et al., 2020; Huang, Wang, et al., 2020; Wen et al., 2020; Xiao, Jiang, et al., 2020; Yu et al., 2020) and 10 studies Fu et al., 2020a Fu et al., , 2020b Huang, Tan, et al., 2020; Huang, Wang, et al., 2020; Wen et al., 2020; Xiao, Tian, et al., 2020; Yang, Sun, et al., 2020; Yu et al., 2020) 

Nine studies Huang, Tan, et al., 2020; Huang, Wang, et al., 2020; F. Liu, 2020; Shi et al., 2020; Xia et al., 2020; Yang, Sun, et al., 2020) 

We assessed publication bias for primary outcome indicators which exceeded 10 articles. These outcome measures include total effective rate, improvement rate of chest CT, rate of disease progression and adverse events. The funnel plots suggested a mild publication bias in total effective rate, improvement rate of chest CT and incidence of adverse events. A severe publication bias was observed in rate of disease progression (Figure 8 ).

We performed a subgroup analysis of the total effective rate based on study type and disease severity. The results of the subgroup Table 4 .

The quality of evidence from RCTs was low (total effective rate, negative conversion rate of nucleic acid, rate of disease progression, and incidence of adverse events) to moderate (improvement rate of chest CT). The quality of evidence from observational studies was very low. The overall quality of evidence was low to moderate ( (Islam et al., 2020) . In addition, many functional food plants with

anti-viral and immunomodulatory properties against SARS-CoV-2 including garlic, ginger, and tea and so on not only could inhibit viral replication but also enhance innate and adaptive immune responses (Upadhyay et al., 2020; Yang, Zhang, Huang et al., 2020 thrombus formation (coagulopathy) and sepsis-related multipleorgan failure, because patients infected with SARS-CoV-2 had higher concentrations and circulating levels of various cytokine than those in healthy adults . But a great number of clinical studies showed that the immunomodulatory botanicals can improve parameters of the immune response, without evidence of risk of overstimulation, and even may have the potential to decrease the risk of a cytokine storm (Brendler et al., 2020) .

In this review, there are several highlights deserved our attention. with RCTs, the treatment regimen they used could provide an option for follow-up of high-quality RCTs.

Although our study can demonstrate the effectiveness of TCM combined with CWM on the treatment of COVID-19, there were several limitations of this systematic review. First, patients infected with SARS-CoV-2 had higher concentrations and circulating levels of various cytokine than those in healthy adults . 

In summary, the results of this review confirmed that integrated TCM and CWM was a potential treatment option to improve the clinical symptoms of COVID-19 patients without increasing the incidence of adverse events. High-quality RCTs are needed to further evaluate the effect of integrated medicine for COVID-19. 

The authors declared that there was no conflict of interest regarding the publication of this paper. 

Ethical approval and patient consent are not required since this is an overview based on published studies.

The data that support the findings of this study are available from the corresponding author upon reasonable request.

https://orcid.org/0000-0002-4462-0549

Botanical drugs and supplements affecting the immune response in the time of COVID-19: Implications for research and clinical practice

Retrospective analysis on clinical efficacy of Ganlu Xiaodu decoction combined with Western medicine in treatment of common COVID-19 patients

Clinical efficacy of Shufeng Jiedu capsule combined with western medicine in treatment of common COVID-19 patients by retrospective analysis

Efficacy analysis on 51 cases of COVID-19 treated with traditional Chinese medicine Lianhua Qingwen: A multi-center retrospective study

Clinical effect and mechanism of Qingfei Touxie Fuzheng recipe in the treatment of Novel Coronavirus pneumonia

Clinical observation on the treatment of mild COVID-19 with Jinhua Qinggan Granules combined with conventional western medicine

Clinical observation on effect of Toujie Quwen granules in treatment of COVID-19

Clinical study on 37 case of COVID-19 treated with integrated traditional Chinese and Western Medicine

Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: A multicenter, prospective, randomized controlled trial

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Clinical efficacy analysis and TCM syndrome characteristics of 72 patients with COVID-19

Natural products and their derivatives against coronavirus: A review of the non-clinical and pre-clinical data

Retrospective study of clinical efficacy of integrated Chinese and western medicine in treatment of COVID-19

Immunomodulatory and anti-SARS activities of Houttuynia cordata

Evaluation on the clinical effect of traditional Chinese medicine and western medicine regimens on COVID-19

Retrospective analysis of 38 cases with COVID-19 treated with integrated traditional Chinese and western medicine

Study on efficacy and safety of TCM decoction in patients with COVID-19

Clinical observation of 42 cases with COVID-19 treated with integrated traditional Chinese and western medicine

Efficacy and safety of integrated traditional Chinese and Western medicine for Corona Virus Disease 2019 (COVID-19): A systematic review and meta-analysis

The add-on effect of Chinese herbal medicine on COVID-19: A systematic review and meta-analysis

Preferred reporting items for systematic reviews and metaanalyses: The PRISMA statement

Yu Yanhong briefing the important role of TCM in COVID-19 containment and treatment

Integrated traditional Chinese and western medicine in the treatment of 40 cases of critical patients with COVID-19

Chinese medical drugs for coronavirus disease 2019: A systematic review and meta-analysis

Efficacy observation of maxing Xuanfei Jiedu decoction on moderate COVID-19 patients

Observation on the clinical effect of Shufeng Jiedu capsule combined with Arbidol Hydrochloride Capsules in the treatment of COVID-19

Clinical observation of 49 cases of non-critical COVID-19 treated by integrated traditional Chinese and western medicine in

RoB 2: A revised tool for assessing risk of bias in randomised trials

Study on clinical efficacy of Lianhua Qingke granule in treatment of mild and ordinary COVID-19

Hanshiyi formula, a medicine for Sars-CoV2 infection in China, reduced the proportion of mild and moderate COVID-19 patients turning to severe status: A cohort study

Evaluation of medicinal herbs as a potential therapeutic option against SARS-CoV-2 targeting its main protease

Exploring an integrative therapy for treating COVID-19: A Randomized Controlled Trial

Preliminary clinical effect analysis of the treatment of novel coronavirus pneumonia by internal administration of traditional Chinese medicine plus fumigation and absorption combined with super dose of vitamin C in treating NOVID-19

The Newcastle Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses

Effect of Xuebijing injection on inflammatory markers and disease outcome of coronavirus disease 2019

Clinical study on 34 case of COVID-19 treated with integrated traditional Chinese and Western Medicine

Efficacy of Huoxiang Zhengqi dropping pills and Lianhua Qingwen granules in treatment of COVID-19: A randomized controlled trial

Value analysis of Shufeng Jiedu Capsule combined with arbidol hydrochloride capsules in the treatment of mild cases of COVID-19

Efficacy of herbal medicine (Xuanfei Baidu decoction) combined with conventional drug in treating COVID-19: A pilot randomized clinical trial

Chinese herbal medicine for coronavirus disease 2019: A systematic review and meta-analysis

Food as medicine: A possible preventive measure against coronavirus disease (COVID-19)

Multicenter clinical observation of Reyanning mixture in treatment of novel coronavirus pneumonia

Retrospective clinical study on treatment of COVID-2019 patients with integrated traditional Chinese and Western medicine

Retrospective clinical analysis on treatment of novel coronavirus-infected pneumonia with traditional Chinese medicine Lianhua Qingwen

Clinical observation of Lianhua Qingwen granule combined with Abidor in the treatment of mild COVID-19

Evaluation of the adjuvant efficacy of natural herbal medicine on COVID-19: A retrospective matched case-control study

The combined therapy of a traditional Chinese medicine formula and Western medicine for a critically ill case infected with COVID-19

Clinical efficacy of Jinyinhua oral liquid in the treatment of 80 patients with coronavirus disease 2019

Observation on the effect of TCM syndrome differentiation on COVID-19

Clinical value of glycyrrhizinate in the treatment of patients with common new coronavirus pneumonia

A novel coronavirus from patients with pneumonia in China

Contribution of traditional Chinese medicine combined with conventional western medicine treatment for the novel coronavirus disease (COVID-19), current evidence with systematic review and meta-analysis

This work was supported by the National Natural Science Foundation of China (NSFC81870005); the Natural Science Foundation of the T A B L E 5 Summary of findings

Traditional Chinese medicine compared to conventional western medicine for